Goldman Sachs Portfolio holdings
Goldman Sachs, founded in 1869 by Marcus Goldman and later joined by Samuel Sachs, is a premier global investment bank headquartered in New York City, renowned for its influential role in financial markets. The firm provides a wide range of services, including investment banking (mergers, acquisitions, and underwriting), securities trading, asset management, and consumer banking through its Marcus platform, catering to corporations, governments, institutions, and high-net-worth individuals. Known for its elite status on Wall Street, Goldman Sachs has a history of navigating major economic events, from the Great Depression to the 2008 financial crisis, where it played a controversial yet pivotal role. With a strong emphasis on innovation and a global footprint, it manages billions in assets and remains a powerhouse in shaping economic policy and market trends.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard Total Bond Market
BND
|
+$1.02B |
| 2 |
Canadian Natural Resources
CNQ
|
+$958M |
| 3 |
iShares Core US Aggregate Bond ETF
AGG
|
+$896M |
| 4 |
Vanguard S&P 500 ETF
VOO
|
+$861M |
| 5 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$756M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$5.62B |
| 2 |
Amgen
AMGN
|
+$1.68B |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.18B |
| 4 |
Visa
V
|
+$1.05B |
| 5 |
Invesco QQQ Trust
QQQ
|
+$1B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 14.79% |
| 2 | Healthcare | 9.32% |
| 3 | Financials | 8.97% |
| 4 | Consumer Discretionary | 7.33% |
| 5 | Industrials | 5.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CEPU
5326
Central Puerto
CEPU
$2.14B
| $113K | ﹤0.01% |
19,073
-6,113
| -24% | -$30.1K |
|
|
FOCL
5327
EDAP TMS S.A.
FOCL
$228M
| $112K | ﹤0.01% |
+10,546
| New | +$103K |
|
5328
Alaunos Therapeutics
TCRT
$4.93M
| $112K | ﹤0.01% |
1,154
-627
| -35% | -$90.9K |
|
5329
ReNew
RNW
$2.23B
| $112K | ﹤0.01% |
+20,338
| New | +$119K |
|
|
NVSAU
5330
DELISTED
New Vista Acquisition Corp Unit
NVSAU
| $111K | ﹤0.01% |
11,033
| – | – |
|
|
TERN
5331
DELISTED
Terns Pharmaceuticals
TERN
| $110K | ﹤0.01% |
10,830
-1,086
| -9% | -$7.23K |
|
5332
Goldgroup Mining Inc.
GORO
$163M
| $110K | ﹤0.01% |
71,879
-7,320
| -9% | -$11.9K |
|
|
WBX
5333
Wallbox
WBX
$81M
| $110K | ﹤0.01% |
1,533
-1,121
| -42% | -$127K |
|
5334
Beyond Air
XAIR
$4.1M
| $109K | ﹤0.01% |
42
-52
| -55% | -$133K |
|
|
SGHLU
5335
DELISTED
Signal Hill Acquisition Corp. Unit
SGHLU
| $108K | ﹤0.01% |
10,600
| – | – |
|
|
ALLG
5336
DELISTED
Allego N.V.
ALLG
| $108K | ﹤0.01% |
34,411
-648
| -2% | -$2.23K |
|
5337
ProKidney
PROK
$343M
| $108K | ﹤0.01% |
+15,722
| New | +$150K |
|
5338
Actinium Pharmaceuticals
ATNM
$23.5M
| $107K | ﹤0.01% |
10,090
+35
| +0.3% | +$355 |
|
5339
Fortress Biotech
FBIO
$92.7M
| $107K | ﹤0.01% |
10,933
+23
| +0.2% | +$255 |
|
|
MOR
5340
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $107K | ﹤0.01% |
30,000
-13
| -0% | -$58 |
|
5341
Zevra Therapeutics
ZVRA
$622M
| $107K | ﹤0.01% |
23,324
-3,089
| -12% | -$15.7K |
|
5342
Traeger
COOK
$189M
| $107K | ﹤0.01% |
755
-20
| -3% | -$3.34K |
|
5343
MoonLake Immunotherapeutics
MLTX
$1.49B
| $106K | ﹤0.01% |
10,110
-100
| -1% | -$889 |
|
5344
Red Robin
RRGB
$151M
| $106K | ﹤0.01% |
19,017
-1,959
| -9% | -$14.6K |
|
|
MESO
5345
Mesoblast
MESO
$1.94B
| $106K | ﹤0.01% |
+18,204
| New | +$114K |
|
5346
Altisource Portfolio Solutions
ASPS
$63.8M
| $105K | ﹤0.01% |
+1,386
| New | +$144K |
|
5347
MediciNova
MNOV
$65.5M
| $105K | ﹤0.01% |
+51,019
| New | +$113K |
|
|
DMTK
5348
DELISTED
DermTech, Inc. Common Stock
DMTK
| $103K | ﹤0.01% |
58,164
-30,481
| -34% | -$81.1K |
|
5349
Bioventus
BVS
$1.03B
| $102K | ﹤0.01% |
39,237
-125,556
| -76% | -$548K |
|
|
GPGI
5350
GPGI Inc
GPGI
$4.41B
| $102K | ﹤0.01% |
24,949
+5,398
| +28% | +$22.4K |
|
Similar funds
Goldman Sachs's Q4 2022 Portfolio in Review
As of Q4 2022, Goldman Sachs held 6,669 positions worth $408B, up 3.1% from $396B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Goldman Sachs withdrew a net $13.2B in Q4 2022, closing 721 positions and reducing 2,588 holdings. Its most notable exit was ChemoCentryx, Inc., an estimated $290M position sold in full.
By sector, the portfolio is most concentrated in Technology at 15% of assets, down from 15% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Goldman Sachs opened a new position in Perfect Corp worth $104M.
- Goldman Sachs's largest Q4 2022 buy was Perfect Corp: 14,518,235 shares worth $104M.
- Goldman Sachs added most to Vanguard Total Bond Market in Q4 2022, an estimated $1.02B increase.
- Goldman Sachs's biggest Q4 2022 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $5.62B.
- Goldman Sachs fully exited ChemoCentryx, Inc. in Q4 2022, selling an estimated $290M.
- Goldman Sachs's ten largest holdings make up 15% of its $408B portfolio in Q4 2022.
- Goldman Sachs opened 429 new positions and closed 721 in Q4 2022.
- Goldman Sachs's portfolio value rose 3.1% quarter-over-quarter to $408B.
Based on Goldman Sachs's 13F filing for Q4 2022, filed 13 Feb 2023.